Galderma Group AG logo

Galderma Group AG (GALD)

Market Closed
12 Jun, 15:20
SIX SIX
172. 15
CHF
+3.6
+2.1359%
CHF
35.09B Market Cap
- P/E Ratio
- Div Yield
418,766 Volume
- Eps
168.55 CHF
Previous Close
Add Transaction
Day Range
169.25 173
Year Range
107.4 173
Want to track GALD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

GALD closed today higher at 172.15 CHF, an increase of 2.1359% from yesterday's close, completing a monthly increase of 4.6823% or 7.7 CHF. Over the past 12 months, GALD stock gained 4.9695%.
GALD pays dividends to its shareholders, with the most recent payment made on Apr 28, 2026. The next estimated payment will be in In 10 months on Apr 28, 2027 for a total of 0.35 CHF.
The last earnings report, released on Mar 05, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 10 different exchanges and in various currencies, with the primary listing on SIX (CHF).

GALD Chart

People also search for

SGS SA
89.48 CHF
+0.6298%
Sonova Holding AG
200.6 CHF
+1.3131%

Galderma Group AG (GALD) FAQ

What is the stock price today?

The current price is 172.15 CHF.

On which exchange is it traded?

Galderma Group AG is listed on SIX.

What is its stock symbol?

The ticker symbol is GALD.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 35.09B.

Has Galderma Group AG ever had a stock split?

No, there has never been a stock split.

Galderma Group AG Profile

Pharmaceuticals Industry
Healthcare Sector
Dr. Flemming Ornskov M.B.A., M.D., M.P.H. CEO
SIX Exchange
CH1335392721 ISIN
CH Country
7,676 Employees
24 Apr 2026 Last Dividend
- Last Split
- IPO Date
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.

Contact Information

Address: Zählerweg 10, Zug, Switzerland, 6300
Phone: 41 58 455 85 92